MHC class II-presented tumor-associated antigen peptides (MHC II-TAA peptides)

MHC class II-presented tumor-associated antigen (TAA) peptides are the molecular targets recognized by CD4+ T-helper cells to initiate and sustain an anti-tumor immune response [1]. In the context of autologous dendritic cell–tumor cell hybrids, these peptides are generated by the fusion of a patient's own dendritic cells with their tumor cells, creating a hybridoma that expresses the full array of patient-specific antigens [2]. This platform leverages the potent costimulatory signals of dendritic cells to present TAAs within the MHC class II pathway, which is crucial for activating T-helper cells that provide essential help for the expansion and memory formation of cytotoxic CD8+ T cells [3]. By presenting a broad, polyclonal spectrum of antigens, this approach aims to overcome tumor heterogeneity and prevent immune escape [2]. Clinically, these complexes are the functional components of personalized cancer vaccines designed to treat various malignancies, including renal cell carcinoma and breast cancer [4]. The interaction between these MHC II-peptide complexes and the T-cell receptor (TCR) is the fundamental step in the therapeutic mechanism of DC-tumor fusion vaccines [1]. This strategy is particularly effective because it bypasses the need to identify specific antigens, instead utilizing the entire tumor-specific peptidome [2]. Safety profiles for therapies targeting these complexes generally show low toxicity, primarily consisting of transient constitutional symptoms [4].

Other names

MHC II-restricted tumor antigensTumor-associated antigen peptidesDC-tumor fusion antigensMHC class II-restricted TAA peptides

Induction of a polyclonal anti-tumor immune response by presenting a broad spectrum of tumor antigens to both CD4+ and CD8+ T cells.